Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults

Journal of Infectious Diseases

Volumn 204, Issue 9, 2011, Pages 1395-1402

  Kennedy, Jeffrey S ^a   Gurwith, Marc ^b   Dekker, Cornelia L ^c   Frey, Sharon E ^d   Edwards, Kathryn M ^e   Kenner, Julie ^f   Lock, Michael ^g   Empig, Cyril ^h   Morikawa, Shigeru ⁱ   Saijo, Masayuki ⁱ   Yokote, Hiroyuki ^j   Karem, Kevin ^k   Damon, Inger ^k   Perlroth, Mark ^c   Greenberg, Richard N ^l  

^a WADSWORTH CENTER   (United States)

^b PaxVax Inc   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Kenner Dermatology Center   (United States)

^g Statistical Consultant   (United States)

^h Peregrine Pharmaceuticals Inc   (United States)

ⁱ NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^j Chemo Sero Therapeutic Research Institute   (Japan)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^l UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LC16M8 VACCINE; MONKEYPOX ANTIBODY; NEUTRALIZING ANTIBODY; SMALLPOX ANTIBODY; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CARDIOTOXICITY; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG SAFETY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; EYELID EDEMA; FACE EDEMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTOXICITY; INJECTION SITE INDURATION; INJECTION SITE PUSTULE; LABORATORY TEST; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONKEYPOX; MULTICENTER STUDY; MYOCARDIAL DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMALLPOX; VACCINIA; VIRUS CULTURE; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; JAPAN; LEUKOCYTES, MONONUCLEAR; MALE; MONKEYPOX VIRUS; SMALLPOX; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA VIRUS; VARIOLA VIRUS; YOUNG ADULT;

EID: 80053426364     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir527     Document Type: Article

References (28)

1. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culturebased live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008; 17:555-64. (Pubitemid 351578172)
2. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009; 8:13-24.
3. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006; 24:7009-22. (Pubitemid 46107176)
4. Meseda CA, Mayer AE, Kumar A, et al. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin Vaccine Immunol 2009; 16:1261-71.
5. Hashizume S. Chiba Serum Institute. Special edition future of vaccination: everything about attenuated vaccines. Basics of new attenuated vaccine strain LC16m8. Clin Virus 1975; 3:229-35.
6. Hirayama M. In search of attenuated vaccine. Clinical special edition: vaccination in futuredeverything about attenuated vaccine. Clin Virus 1975; 3:269-79.
7. Saito T, Fujii T, Kanatani Y, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009; 301:1025-33.
8. Newman FK, Frey SE, Blevins TP, et al. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 2003; 41:3154-7. (Pubitemid 36842314)
9. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004; 325:425-31. (Pubitemid 38902805)
10. Viner KM, Isaacs SN. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 2005; 7:579-83. (Pubitemid 40720410)
11. Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009; 90:1962-6.
12. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346:1265-74. (Pubitemid 34429457)
13. Military Vaccine Agency, Army Medical Command, U.S. Dept of Defense. National Immunization Program, CDC. Cardiac adverse events following smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:248-50.
14. Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008; 7:1225-37.
15. Engelstad M, Howard ST, Smith GL. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 1992; 188:801-10.
16. Empig C, Kenner JR, Perret-Gentil M, et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006; 24:3686-94.
17. Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008; 89:2992-7.
18. Benhnia MR, McCausland MM, Su HP, et al. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 2008; 82:3751-68. (Pubitemid 351429950)
19. Saijo M, Ami Y, Suzaki Y, et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 2006; 80:5179-88.
20. Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005; 294:2734-43.
21. Morgan J, Roper MH, Sperling L, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis 2008; 46(Suppl 3):S242-50. (Pubitemid 351590137)
22. Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972; 21:214-8.
23. Sarkar JK, Mitra AC, MukherjeeMK. The minimum protective level of antibodies in smallpox. BullWorld Health Organ 1975; 52:307-11.
24. Sirven P, Castelli FA, Probst A, Szely N, Maillere B. In vitro human CD41 T cell response to the vaccinia protective antigens B5R and A33R. Mol Immunol 2009; 46:1481-7.
25. Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. J Virol 2006; 80:10010-20. (Pubitemid 44522595)
26. Gordon SN, Cecchinato V, Andresen V, et al. Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 2011; 203:1043-53.
27. Weinzierl AO, Rudolf D, Maurer D, et al. Identification of HLA-A*01-and HLA-A*02-restricted CD81T-cell epitopes shared among group B enteroviruses. J Gen Virol 2008; 89:2090-7.
28. Yue Y, Gui J, Xu W, Xiong S. Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization. Mol Immunol 2011; 48:706-13.